Active material: Framycetin
When ATH: R01AX08
CCF: Antibacterial drug for local use in ENT practice
ICD-10 codes (testimony): J00, J01, J31, J32, Z29.2, Z29.8
When CSF: 06.05.04
Manufacturer: Laboratoires Bouchara-RECORDATI (France)
| Spray nazalynыy 1.25% | 1 ml |
| framycetin sulfate | 12.5 mg (8 th. ME) |
Excipients: metilparagidroksiʙenzoat, sodium chloride, lemon acid, water distillirovannaya.
15 мл – флаконы полиэтиленовые (1) в комплекте с распылителем – пачки картонные.
Aminoglycoside antibiotic for topical use in otorhinolaryngology. Effective bactericidal. It is active against Gram-positive and Gram-negative bacteria, causing the development of infectious processes in the upper respiratory tract.
Research pharmacokinetics Izofra not conducted in connection with low systemic absorption.
In the combined therapy in infectious and inflammatory diseases of the upper respiratory tract, including:
Prevention and treatment of inflammatory processes after surgery.
Adults appoint 1 injection into each nostril 4-6 time / day.
Babies appoint 1 injection into each nostril 3 times / day.
Средняя продолжительность курса терапии – 7 days.
By drinking a bottle should be kept in the upright position.
Allergic reactions: в единичных случаях – кожные проявления.
Adequate and well-controlled clinical studies safety of the drug Izofra during pregnancy and lactation (breast-feeding) not performed.
If during the 7 days of treatment with a therapeutic effect is weak or absent, the drug should be abolished.
Due to the low degree of absorption into the systemic circulation overdose is unlikely.
No clinically significant drug interactions Izofra with other drugs have been identified.
The drug is released under the prescription.
The drug should be stored at temperatures above 25 ° C. Shelf life - 3 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More